Disease: Respiratory syncytial virus infection

NIRSE-GAL

Spain
|
2023-2026
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

PRIPASCO

Spain
|
2023-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • Respiratory syncytial virus
  • Bordetella pertussis
  • Respiratory syncytial virus infection
  • Pertussis
  • Blood sample
  • Nasopharyngeal swab

IMAR

Sweden
|
2018-2022
  • General population
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • Intensive care unit
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

MIViral

Switzerland
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

Nur Vural

Türkiye
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Non pharmacological intervention
  • Lung ultrasound

BronchSTART

United Kingdom Ireland
|
2021-2026
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Joseph

Switzerland
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Lihou

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Cocchi

Italy
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab